| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Sep―08 |
Socioeconomic vulnerability and osteoporosis treatment disparities during COVID-19 lockdown among U.S. medicare enrollees who initiated romosozumab |
Ye Liu, Tarun Arora, Jingyi Zhang, Bisakha Sen, David Becker, Ruoyan Sun, et al. (+3) Huifeng Yun, Kenneth G. Saag, Jeffrey R. Curtis |
| 2 |
[GO] |
2024―May―25 |
Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019-2023 |
K.J. Knight, R.J. Fordham, N.J. Crabtree, K.M. Knapp |
| 3 |
[GO] |
2023―Oct―28 |
Vaccination against COVID-19 reduced the mortality risk of COVID-positive hip fracture patients to baseline levels: the nationwide data-linked IMPACT Protect study |
Andrew J. Hall, N. D. Clement, A. M. J. MacLullich, T. O. White, A. D. Duckworth |
| 4 |
[GO] |
2023―Oct―06 |
Improvement of proportion of days covered for denosumab under implementation of clinical pharmacist adherence management system: normal and COVID-19 period |
Qiong Yang, Junhong He, Fangfang Yuan |
| 5 |
[GO] |
2023―Sep―13 |
Association of prior treatment with nitrogen-containing bisphosphonates on outcomes of COVID-19 positive patients |
R.H. Lee, J. Curtis, M.T. Drake, S. Bobo Tanner, L. Lenert, K. Schmader, et al. (+3) C. Pieper, R. North, K.W. Lyles |
| 6 |
[GO] |
2022―Dec―17 |
Impact of the COVID-19 pandemic on osteoporotic hip fractures among outpatients in Germany |
Karel Kostev, Christian Tanislav |
| 7 |
[GO] |
2022―Jul―09 |
Surgical treatment for fragility hip fractures during the COVID-19 pandemic resulted in lower short-term postoperative functional outcome and a higher complication rate compared to the pre-pandemic period |
Chirathit Anusitviwat, Ekasame Vanitcharoenkul, Pojchong Chotiyarnwong, Aasis Unnanuntana |
| 8 |
[GO] |
2022―Jan―23 |
COVID pandemic and denosumab adherence |
S. Minisola, C. Cipriani, E. Vigna, C. Sonato, L. Colangelo, F. Monti, J. Pepe |
| 9 |
[GO] |
2021―Aug―21 |
Adherence to dosing schedule of denosumab therapy for osteoporosis during COVID-19 lockdown: an electronic medical record and pharmacy claims database study from Asia |
Manju Chandran, Ying Hao, Ann Kerwen Kwee, Mcvin Hua Heng Cheen, Yun Ann Chin, Valerie Yun Ting Ng |
| 10 |
[GO] |
2021―Aug―17 |
No association of anti-osteoporosis drugs with COVID-19-related outcomes in women: a nationwide cohort study |
A. Atmaca, I. Demirci, C. Haymana, I. Tasci, I. Sahin, E. Cakal, et al. (+12) N. Ata, S. Dagdelen, S. Salman, R. Emral, M. Sahin, O. Celik, T. Demir, D. Ertugrul, U. Unluturk, M. Caglayan, I. Satman, A. Sonmez |
| 11 |
[GO] |
2021―Jul―14 |
Retraction Note to: Comment on an article: “Osteoporosis in the age of COVID-19 patients” |
O. Ć. Ibrahimagić, A. Vujadinović, Z. Ercegović, S. Kunić, Dž. Smajlović, Z. Dostović |
| 12 |
[GO] |
2021―Mar―09 |
Correction to: How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey |
N.R. Fuggle, A. Singer, C. Gill, A. Patel, A. Medeiros, A.S. Mlotek, et al. (+6) D.D. Pierroz, P. Halbout, N.C. Harvey, J.-Y. Reginster, C. Cooper, S.L. Greenspan |
| 13 |
[GO] |
2021―Mar―04 |
Reply to Comment on “Osteoporosis in the Age of COVID-19” |
C. M. Girgis, R. J. Clifton-Bligh |
| 14 |
[GO] |
2021―Feb―18 |
Virtual fracture liaison clinics in the COVID era: an initiative to maintain fracture prevention services during the pandemic associated with positive patient experience |
S. English, L. Coyle, S. Bradley, W. Wilton, J. Cordner, R. Dempster, J.R. Lindsay |
| 15 |
[GO] |
2021―Feb―09 |
How has COVID-19 affected the treatment of osteoporosis? An IOF-NOF-ESCEO global survey |
N. R. Fuggle, A. Singer, C. Gill, A. Patel, A. Medeiros, A. S. Mlotek, et al. (+6) D. D. Pierroz, P. Halbout, C. N. Harvey, J.-Y. Reginster, C. Cooper, S. L. Greenspan |
| 16 |
[GO] |
2021―Feb―09 |
COVID-19 and effects on osteoporosis management: the patient perspective from a National Osteoporosis Foundation survey |
A.J. Singer, N.R. Fuggle, C.B. Gill, A.R. Patel, A.P. Medeiros, S.L. Greenspan |
| 17 |
[GO] |
2021―Jan―30 |
The incidence of arm, forearm, and hip osteoporotic fractures during early stage of COVID-19 pandemic |
W. Pluskiewicz, R. Wilk, P. Adamczyk, M. Hajzyk, M. Swoboda, A. Sladek, B. Koczy |
| 18 |
[GO] |
2021―Jan―21 |
Comment on an article: “Osteoporosis in the age of COVID-19 patients” |
O. Ć. Ibrahimagić, A. Vujadinović, Z. Ercegović, S. Kunić, Dž. Smajlović, Z. Dostović |
| 19 |
[GO] |
2020―Nov―04 |
A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic |
H.R. Sapkota, A. Nune, J. Bateman, S. Venkatachalam |
| 20 |
[GO] |
2020―Oct―14 |
Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures |
E. V. McCloskey, N. C. Harvey, H. Johansson, M. Lorentzon, L. Vandenput, E. Liu, J. A. Kanis |
| 21 |
[GO] |
2020―Oct―13 |
Sex-specific association between vitamin D deficiency and COVID-19 mortality in older patients |
M. Hars, A. Mendes, C. Serratrice, F.R. Herrmann, G. Gold, C. Graf, et al. (+2) D. Zekry, A. Trombetti |
| 22 |
[GO] |
2020―Aug―10 |
Disruption of bone densitometry practice in a Northern Italy Orthopedic Hospital during the COVID-19 pandemic |
C. Messina, A. C. Buzzoni, S. Gitto, J. Almolla, D. Albano, L. M. Sconfienza |
| 23 |
[GO] |
2020―Jun―16 |
Identifying and managing osteoporosis before and after COVID-19: rise of the remote consultation? |
Z. Paskins, F. Crawford-Manning, L. Bullock, C. Jinks |
| 24 |
[GO] |
2020―Jun―09 |
What can we learn about corticosteroid therapy as a treatment for COVID-19? |
J. Tang |
| 25 |
[GO] |
2020―Apr―28 |
Osteoporosis in the age of COVID-19 |
C. M. Girgis, R. J. Clifton-Bligh |
